GlassScriptPhysician profile
Brittany R Hendrix
NPI 1871057257
$2,552.25
in general payments reported to CMS, 2019-2025
19 companies · $792 in 2025
The $792 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $645 · 2024: $1,115 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $694.84 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $273.86 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.05 | 2023-2025 | Relistor, Xifaxan |
| Pfizer INC. | $187.53 | 2023-2025 | |
| Abbvie INC. | $185.28 | 2023-2025 | |
| Amgen INC. | $170.29 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $141.67 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $126.63 | 2023-2025 | |
| Lundbeck LLC | $111.71 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $104.55 | 2024-2025 | |
| Shield Therapeutics INC | $72.45 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.83 | 2023-2025 | Caplyta |
| Scilex Pharmaceuticals INC. | $35.84 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $33.65 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $25.20 | 2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $21.40 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $21.19 | 2023 | Auvelity |
| Glaxosmithkline, LLC. | $16.22 | 2023 | Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $16.06 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.